{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:10:42Z","timestamp":1789387842643,"version":"build-2803163510"},"reference-count":156,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T00:00:00Z","timestamp":1300233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FEBS Letters"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:p>Interleukin (IL)\u20106 is a cytokine with multiple biological activities. It contributes to host defense against pathogens, whereas accelerated production of IL\u20106 plays a significant pathological role in various diseases. Clinical trials have demonstrated the efficacy of tocilizumab, a humanized anti\u2010IL\u20106 receptor antibody, for patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis, leading to approval of this innovative drug for the treatment of these diseases. Since IL\u20106 has been demonstrated to play a significant role in the development of various other autoimmune and inflammatory diseases, tocilizumab can be expected to become a novel drug for such diseases as well.<\/jats:p>","DOI":"10.1016\/j.febslet.2011.03.023","type":"journal-article","created":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T08:31:58Z","timestamp":1300350718000},"page":"3699-3709","source":"Crossref","is-referenced-by-count":125,"title":["Anti\u2010interleukin\u20106 receptor antibody, tocilizumab, for the treatment of autoimmune diseases"],"prefix":"10.1002","volume":"585","author":[{"given":"Toshio","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Narazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamitsu","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/324073a0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3136546"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90411-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.4.1120.1120"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8511589"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90333-6"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2225"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1411569"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1957"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901464"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115806"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.1.1.1"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200420945"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502257102"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040391"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.141.5.1543"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1391"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00151-0"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650110113"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.6.3353"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1621100"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11143"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.16.6367"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12483971"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.1.228"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.4.1360.1360"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830181122"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0338"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155846"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60784-3"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.14.8222"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.4.461"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199908)42:8<1635::AID-ANR11>3.0.CO;2-Q"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2000.4989"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068064"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0125-1"},{"key":"e_1_2_8_42_1","doi-asserted-by":"crossref","unstructured":"Kremer J.L. Blanco R. Brzosko M. Burgos-Vargas R. Halland A.M. Vernon E. Ambs P. and Fleischmann R. (2010) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate response to methotrexate at 1 year: the LITHE study. Arthritis Rheum. (Epub ahead of print).","DOI":"10.1002\/art.30158"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.70"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126573"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2005.08.014"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.12.096"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2443.2005.00900.x"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22118"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099267"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1185-0"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1422-6"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.1.56"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4602"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.41"},{"key":"e_1_2_8_56_1","first-page":"1403","article-title":"Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis","volume":"24","author":"De Benedetti F.","year":"1997","journal-title":"J. Rheumatol."},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.2741\/1690"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20944"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"e_1_2_8_60_1","first-page":"146","article-title":"From biology to classification and targeted therapy in juvenile idiopathic arthritis","volume":"69","author":"De Benedetti F.","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.08.006"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10620"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0116-2"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.088179"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1097-z"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep441"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1418-2"},{"key":"e_1_2_8_68_1","first-page":"141","article-title":"Successful treatment with tocilizumab in a patient with refractory adult-onset Still&rsquo;s disease (AOSD)","volume":"28","author":"Yoshimura M.","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1553-9"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.8.4.287"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.36.1.45"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.1999.01989.x"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.9.4878"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.012"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.01.001"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61077-6"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401022"},{"key":"e_1_2_8_78_1","first-page":"395","article-title":"Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids","volume":"26","author":"Cimmino M.A.","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20901"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.103663"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091185"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1985.03360190069027"},{"key":"e_1_2_8_83_1","first-page":"91","article-title":"Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan: clinical, radiological, and cytokine studies of 13 patients","volume":"22","author":"Oide T.","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032995"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1142-x"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep412"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.09.004"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.59"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei266"},{"key":"e_1_2_8_90_1","first-page":"1788","article-title":"Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions?","volume":"100","author":"Moris M.","year":"1999","journal-title":"Circulation"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23373"},{"key":"e_1_2_8_92_1","doi-asserted-by":"crossref","unstructured":"Seitz M. Reichenbach S. Bonel H.M. Adler S. Wermelinger F. and Villiger P.M. (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. Swiss Med. Wkly (Epub ahead of print).","DOI":"10.4414\/smw.2011.13156"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000030185.67510.C0"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000066907.83923.32"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.01.001"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.047"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00290261"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10177"},{"key":"e_1_2_8_100_1","first-page":"2285","article-title":"Th1\/Th17 cytokine profiles in patients with reactive arthritis\/undifferentiated spondyloarthropathy","volume":"34","author":"Singh R.","year":"2007","journal-title":"J. Rheumatol."},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24899"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.12.1330"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126706"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.09.011"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.08.004"},{"key":"e_1_2_8_106_1","doi-asserted-by":"crossref","unstructured":"Shima Y. Tomita T. Ishii T. Morishima A. Maeda Y. Ogata A. Kishimoto T. and Tanaka T. (2011) Tocilizumab a humanized anti-interleukin-6 receptor antibody ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod. Rheumatol. (Epub ahead of print).","DOI":"10.1007\/s10165-011-0416-9"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2006.07.018"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20613"},{"key":"e_1_2_8_109_1","first-page":"319","article-title":"Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis","volume":"48","author":"Kawai M.","year":"2009","journal-title":"Rheumatology"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0806188"},{"key":"e_1_2_8_111_1","first-page":"308","article-title":"Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis","volume":"25","author":"Hasegawa M.","year":"1998","journal-title":"J. Rheumatol."},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(01)00128-1"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700109"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.7.3423"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken145"},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq275"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096677"},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.2"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400514"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2990.1998.00092.x"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.03.026"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24689"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04239-2"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.147.1.117"},{"key":"e_1_2_8_125_1","first-page":"565","article-title":"Cytokine production, serum levels and disease activity in systemic lupus erythematosus","volume":"18","author":"Grondal G.","year":"2000","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_8_126_1","doi-asserted-by":"publisher","DOI":"10.1177\/096120339600500603"},{"key":"e_1_2_8_127_1","first-page":"16","article-title":"Urinary levels of IL-6 in patients with active lupus nephritis","volume":"40","author":"Iwano M.","year":"1993","journal-title":"Clin. Nephrol."},{"key":"e_1_2_8_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330506"},{"key":"e_1_2_8_129_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00612.x"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02433.x"},{"key":"e_1_2_8_131_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27221"},{"key":"e_1_2_8_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.02.011"},{"key":"e_1_2_8_133_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0367-9"},{"key":"e_1_2_8_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/0008-8749(92)90207-6"},{"key":"e_1_2_8_135_1","first-page":"1544","article-title":"Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet&rsquo;s disease. A comparative study with familial Mediterranean fever and healthy subjects","volume":"20","author":"Mege J.L.","year":"1993","journal-title":"J. Rheumatol."},{"key":"e_1_2_8_136_1","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1996.4268"},{"key":"e_1_2_8_137_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42440"},{"key":"e_1_2_8_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2010.04.009"},{"key":"e_1_2_8_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.016"},{"key":"e_1_2_8_140_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36532"},{"key":"e_1_2_8_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(91)90073-G"},{"key":"e_1_2_8_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(95)00155-7"},{"key":"e_1_2_8_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0502-500"},{"key":"e_1_2_8_144_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830200134"},{"key":"e_1_2_8_145_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802218105"},{"key":"e_1_2_8_146_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.72"},{"key":"e_1_2_8_147_1","doi-asserted-by":"crossref","unstructured":"Uzawa A. Mori M. Ito M. Uchida T. Hayakawa S. Masuda S. and Kuwabara S. (2009) Markedly increased CSF interleukin-6 levels in neuromyelitis optica but not in multiple sclerosis. J. Neurol. (Epub ahead of print).","DOI":"10.1007\/s00415-009-5274-4"},{"key":"e_1_2_8_148_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207450903428970"},{"key":"e_1_2_8_149_1","first-page":"182","article-title":"Advances in the understanding of acquired hemophilia A: implications for clinical practice","volume":"148","author":"Collins P.W.","year":"2009","journal-title":"Br. J. Haematol."},{"key":"e_1_2_8_150_1","doi-asserted-by":"crossref","unstructured":"Nishida S. Kawasaki T. Kashiwagi H. Morishima A. Hishitani Y. Kawai M. Hirano T. Ishii T. Hagihara K. Shima Y. Narazaki M. Ogata A. Oka Y. Kishimoto T. and Tanaka T. (2011) Successful treatment of acquired hemophilia A complicated by chronic GVHD with tocilizumab. Mod. Rheumatol. (Epub ahead of print).","DOI":"10.1007\/s10165-010-0411-6"},{"key":"e_1_2_8_151_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1682"},{"key":"e_1_2_8_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80721-7"},{"key":"e_1_2_8_153_1","unstructured":"Vaitla P.M. Radford P.M. Tighe P.J. Powell R.J. McDermott E.M. Todd I. and Drewe E. (2011) Role of interleukin-6 (IL-6) in a patient with TRAPS revealed by treatment with tocilizumab (anti-IL-6 receptor monoclonal antibody). Arthritis Rheum. (Epub ahead of print)."},{"key":"e_1_2_8_154_1","doi-asserted-by":"crossref","unstructured":"Campbell L. Chen C. Bhagat S.S. Parker R.A. and Ostor A.J. (2010) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systemic literature review and meta-analysis of randomized controlled trials. Rheumatology (Epub ahead of print).","DOI":"10.1093\/rheumatology\/keq343"},{"key":"e_1_2_8_155_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0102-75"},{"key":"e_1_2_8_156_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq030"},{"key":"e_1_2_8_157_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24126"}],"container-title":["FEBS Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.febslet.2011.03.023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.febslet.2011.03.023","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.febslet.2011.03.023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T19:13:29Z","timestamp":1694978009000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1016\/j.febslet.2011.03.023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,16]]},"references-count":156,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1016\/j.febslet.2011.03.023"],"URL":"https:\/\/doi.org\/10.1016\/j.febslet.2011.03.023","archive":["Portico"],"relation":{},"ISSN":["0014-5793","1873-3468"],"issn-type":[{"value":"0014-5793","type":"print"},{"value":"1873-3468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,16]]}}}